Related Experiment Video
Updated: Feb 21, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Inflammatory Biomarkers and Liver Histopathology in Non-Uremic and Uremic Chronic Hepatitis C Patients
Bengu Tatar1, Sukran Kose2, Emel Pala3
1University of Health Science, Izmir Tepecik Education and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Izmir, Turkey. b.gtatar@hotmail.com.
Insights
In chronic hepatitis C (cHepC) patients, YKL-40 and APRI score correlate with liver fibrosis. For those with end-stage renal disease (ESRD), APRI score may offer insights into fibrosis progression.
Area of Science:
- Hepatology
- Nephrology
- Inflammation Research
Background:
- Chronic hepatitis C (cHepC) is a significant cause of liver disease.
- Assessing liver fibrosis and inflammation is crucial for managing cHepC.
- Uremia in cHepC patients may alter disease progression and biomarker profiles.
Purpose of the Study:
- To investigate the association between liver fibrosis and inflammation biomarkers.
- To compare these associations in non-uremic versus uremic (ESRD) cHepC patients.
Main Methods:
- Liver biopsy analysis using the modified ISHAC scoring system in 50 cHepC patients.
- Measurement of inflammation markers: YKL-40, neutrophil/lymphocyte ratio (NLR), thrombocyte/lymphocyte ratio (PLR), CRP, and immunoglobulins (IgG, A, M).
- Evaluation of AST to Platelet Ratio Index (APRI) score and fibrosis staging (FS).
Main Results:
- cHepC patients exhibited elevated inflammation compared to healthy controls.
- End-stage renal disease (ESRD) patients showed higher inflammation markers but lower fibrosis scores (FS) and hepatic activity index (HAI).
- In non-uremic patients, YKL-40 and APRI score were independently associated with FS; in ESRD patients, only APRI score showed independent association with FS.
Conclusions:
- YKL-40 and APRI score may serve as valuable non-invasive markers for liver fibrosis in non-uremic cHepC patients.
- In cHepC patients with ESRD, APRI score appears more informative than other markers for predicting liver fibrosis.
- Further research is needed to fully elucidate fibrosis prediction in cHepC patients with ESRD.
Background:
The aim of this study is to investigate the association between hepatic activity index (HAI) and fibrosis score (FS) with inflammation biomarkers in non-uremic and uremic hepatitis C positive patients.
Methods:
Fifty chronic hepatitis C (cHepC) positive patients, having a liver biopsy were included in this study. Liver biopsies were scored according to modified ISHAC scoring system. 25 healthy controls of similar age and gender were also enrolled as control group. Serum YKL-40, neutrophil/lymphocyte ratio (NLR), thrombocyte/lymphocyte ratio (PLR), CRP and Immunoglobulin (IgG, A and M) levels were used to determine inflammation. AST to Platelet Ratio Index (APRI) score was also evaluated. According to biopsy findings patients were divided into 2 groups: low (0-2) and severe (3-6) FS.
Results:
Patients with cHepC had increased inflammation compared to the healthy controls. End-stage renal disease (ESRD) patients had higher levels of inflammation markers (NLR, IgG, CRP and YKL-40) and lower HCV RNA levels, HAI and FS compared to non-uremic patients. When patients were grouped into 2 according to FS as mild and severe, IgG (p < 0.001), YKL-40 (p = 0.02) levels and APRI score (p = 0.002) were significantly higher compared to mild FS (p = 0.002). YKL-40 levels (t value: 3.48; p = 0.001) and APRI score (t value: 4.57, p < 0.001) were found as independent associated with FS in non-uremic patients. However, in adjusted models, only APRI score (t value: 3.98, p = 0.002) was an independent associated with FS in ESRD patients.
Conclusion:
In non-uremic cHepC patients, YKL-40 levels and APRI score may be valuable markers of FS. In ESRD patients, there is not sufficient data for prediction of HAI and FS. In these patients, APRI score may provide better information.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

